Abstract
BackgroundThe rapid clinical translation of mesenchymal stem cells (MSC) has resulted in the development of cell-based strategies for multiple indications. Unfortunately one major barrier to widespread implementation of MSC-based therapies is the limited supply of fetal calf serum (FCS) used to expand cells to therapeutic numbers. Additionally, the xenogeneic element of fetal calf serum has been previously demonstrated to stimulate antibody mediated reactions and in some cases sensitization leading to anaphylaxis.MethodXcytePLUS™ media, a human platelet lysate based product, was used to supplement the culture medium at 5, 7.5 and 10% and compared to fetal calf serum at 10%, for human umbilical cord MSC expansion. Properties of the expanded cells were investigated.ResultsThis study demonstrated equivalent or superior effects of human platelet lysate compared to standard FCS supplemented media, based on doubling rate, without loss of identity or function, as demonstrated with flow cytometry characterization. Differentiation into osteocytes, adipocytes and chondrocytes was comparable from cells expanded in either media supplement.ConclusionsThese data support the implementation of human platelet lysate supplemented media as an alternative to xenogeneic containing preparations which may lead to safer MSC products with therapeutic uses.
Highlights
The rapid clinical translation of mesenchymal stem cells (MSC) has resulted in the development of cell-based strategies for multiple indications
Differentiation into osteocytes, adipocytes and chondrocytes was comparable from cells expanded in either media supplement. These data support the implementation of human platelet lysate supplemented media as an alternative to xenogeneic containing preparations which may lead to safer MSC products with therapeutic uses
Doubling rate superior with WJ‐MSC cultured in XCyte Media versus fetal calf serum (FCS) Wharton’s Jelly MSC (WJ-MSC) after 5 passages were plated in media containing 5, 7.5 and 10% XcytePLUSTM, or 10% FCS supplemented media and cultured for 9 days
Summary
The rapid clinical translation of mesenchymal stem cells (MSC) has resulted in the development of cell-based strategies for multiple indications. A number of clinical trials have been performed utilizing MSC in conditions ranging from hepatic failure [12], type 1 diabetes [13], and stroke [14]. The majority of these clinical trials have utilized MSCs that are grown in FCS containing media. Overall safety has been demonstrated of MSC, as reported in a meta-analysis of clinical trials containing over 1,000 patients [15]. In these trials administration doses were 1–3 injections, substantially decreasing the possibility of sensitization. Le Blanc et al demonstrated in 12 patients being administered bone marrow MSC for treatment of steroid resistant graft versus host disease (GVHD) the development of antibodies to fetal calf serum proteins as detected by ex vivo treatment of fetal calf proteins [16]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
